SNN vs UTHR
Smith & Nephew plc vs United Therapeutics — AI-powered side-by-side comparison
SNN
Smith & Nephew plc
59
Watch
VS
UTHR
United Therapeutics
72
Buy
| Metric | SNN | UTHR |
|---|
| AI Score |
59
|
72
|
| Price |
$30.05
|
$514.89
|
| P/E Ratio |
19.70×
|
17.05×
|
| ROE |
11.8%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.2%
|
86.1%
|
| Debt / Equity |
0.73×
|
0.00×
|
| Dividend Yield |
2.6%
|
0.0%
|
| RSI (14) |
40.7
|
52.2
|
| Beta |
0.688
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for SNN versus UTHR.
UTHR leads by 13 points.
UTHR scores 72/100 (Buy) versus SNN at 59/100 (Watch).
SNN Committee View
40% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Technical Analyst remains cautious — price structure making lower highs and lower lows. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Dividend yield of 2.7% pays you to wait — Value
- EPS growing 52.3% YoY — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.